{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:07:24Z","timestamp":1781716044029,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s15010-025-02512-0","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T05:40:17Z","timestamp":1743313217000},"page":"1483-1489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical and microbiologic outcomes of Stenotrophomonas maltophilia bloodstream infections"],"prefix":"10.1007","volume":"53","author":[{"given":"Sunish","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianne","family":"Slaven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd G.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan K.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"2512_CR1","doi-asserted-by":"crossref","unstructured":"Palleroni NJ, Bradbury JF. Stenotrophomonas, a new bacterial genus for Xanthomonas maltophilia (Hugh 1980) swings et al. 1983. Int J Syst Bacteriol. 1993;43(3):606\u20139.","DOI":"10.1099\/00207713-43-3-606"},{"key":"2512_CR2","doi-asserted-by":"crossref","unstructured":"Tamma PD, Heil E, Justo J, Mathers AJ, Satlin M, Bonomo R. Infectious diseases society of America 2024 guidance on the treatment of antimicrobial resistant Gram-Negative infections. Clin Infect Dis. 2024 Jul 18.","DOI":"10.1093\/cid\/ciae403"},{"key":"2512_CR3","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.2147\/IDR.S416678","volume":"16","author":"P Boonmee","year":"2023","unstructured":"Boonmee P, Nasomsong W, Lorchirachoonkul N, Pungcharoenkijkul S, Juntanawiwat P, Chaemchaeng S, Santimaleeworagun W. The activities of antimicrobials against Stenotrophomonas maltophilia isolates and evaluation of clinical outcomes among treatment regimens in patients with Stenotrophomonas maltophilia infections: A retrospective multicenter cohort study. Infect Drug Resist. 2023;16:5173\u201384.","journal-title":"Infect Drug Resist"},{"issue":"2","key":"2512_CR4","doi-asserted-by":"publisher","first-page":"ofab644","DOI":"10.1093\/ofid\/ofab644","volume":"9","author":"SH Sarzynski","year":"2022","unstructured":"Sarzynski SH, Warner S, Sun J, Matsouaka R, Dekker JP, Babiker A, Li W, Lai YL, Danner RL, Fowler VG Jr, Kadri SS. Trimethoprim-Sulfamethoxazole versus Levofloxacin for Stenotrophomonas maltophilia infections: A retrospective comparative effectiveness study of electronic health records from 154 US hospitals. Open Forum Infect Dis. 2022;9(2):ofab644.","journal-title":"Open Forum Infect Dis"},{"key":"2512_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1128\/AAC.01324-13","volume":"58","author":"YL Wang","year":"2014","unstructured":"Wang YL, Scipione MR, Dubrovskaya Y, Papadopoulos J. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 2014;58:176\u201382.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2512_CR6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.cmi.2018.11.008","volume":"25","author":"JH Ko","year":"2019","unstructured":"Ko JH, Kang CI, Cornejo-Juarez P, et al. Fluoroquinolones versus Trimethoprim sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis. Clin Microbiol Infect. 2019;25(5):546\u201354.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"2512_CR7","doi-asserted-by":"publisher","first-page":"ofaa141","DOI":"10.1093\/ofid\/ofaa141","volume":"7","author":"B Cai","year":"2020","unstructured":"Cai B, Tillotson G, Benjumea D, Callahan P, Echols R. The burden of bloodstream infections due to Stenotrophomonas maltophilia in the united States: A large, retrospective database study. Open Forum Infect Dis. 2020;7(5):ofaa141.","journal-title":"Open Forum Infect Dis"},{"key":"2512_CR8","unstructured":"FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria. https:\/\/www.fda.gov\/drugs\/development-resources\/fda-recognized-antimicrobial-susceptibility-test-interpretive-criteria"},{"key":"2512_CR9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.2517-6161.1991.tb01848.x","volume":"53","author":"Rosenbaum","year":"1991","unstructured":"Rosenbaum. A characterization of optimal designs for observational studies. J Roy Stat Soc. 1991;53:597\u2013610.","journal-title":"J Roy Stat Soc"},{"key":"2512_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"P Rosenbaum","year":"1983","unstructured":"Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41\u201355.","journal-title":"Biometrika"},{"key":"2512_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","volume":"39","author":"P Rosenbaum","year":"1985","unstructured":"Rosenbaum P, Rubin D. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33\u20138.","journal-title":"Am Stat"},{"key":"2512_CR12","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1214\/08-AOAS187","volume":"2","author":"D Rubin","year":"2008","unstructured":"Rubin D. For objective causal inference, design Trumps analysis. Ann Appl Stat. 2008;2:808\u201340.","journal-title":"Ann Appl Stat"},{"key":"2512_CR13","unstructured":"Lehmann EL, D\u2019Abrera HJ, Nonparametrics. Statistical methods based on ranks. Holden-Day. 1975."},{"key":"2512_CR14","unstructured":"R Core Team. R Foundation for Statistical Computing. 2016."},{"issue":"3","key":"2512_CR15","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1128\/AAC.48.3.946-953.2004","volume":"48","author":"BB Ba","year":"2004","unstructured":"Ba BB, Feghali H, Arpin C, Saux MC, Quentin C. Activities of Ciprofloxacin and Moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother. 2004;48(3):946\u201353.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2512_CR16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/infdis\/142.4.602","volume":"142","author":"VL Yu","year":"1980","unstructured":"Yu VL, Felegie TP, Yee RB, Pasculle AW, Taylor FH. Synergistic interaction in vitro with use of three antibiotics simultaneously against Pseudomonas maltophillia. J Infect Dis. 1980;142(4):602\u20137.","journal-title":"J Infect Dis"},{"key":"2512_CR17","doi-asserted-by":"crossref","unstructured":"Biagi M, Vialichka A, Jurkovic M et al. Activity of Cefiderocol alone and in combination with Levofloxacin, Minocycline, polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2020; 64(9).","DOI":"10.1128\/AAC.00559-20"},{"issue":"8","key":"2512_CR18","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1093\/jac\/dkab134","volume":"76","author":"T Babich","year":"2021","unstructured":"Babich T, Naucler P, Valik JK, et al. Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study. J Antimicrob Chemother. 2021;76(8):2172\u201381.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2512_CR19","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1093\/jac\/dkz116","volume":"74","author":"MD Shah","year":"2019","unstructured":"Shah MD, Coe KE, El Boghdadly Z, Wardlow LC, Dela-Pena JC, Stevenson KB, Reed EE. Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia. J Antimicrob Chemother. 2019;74(7):2055\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"2512_CR20","doi-asserted-by":"crossref","unstructured":"Brenton C, Hall J, Ortwine W, Wei N, Mang BC, Prokesch. Elisa Pichlinski, 1491. Standard- vs. High-dose Trimethoprim-Sulfamethoxazole for Stenotrophomonas maltophilia pneumonia, Open Forum Infectious Diseases, Volume 7, Issue Supplement_1, October 2020, Page S747.","DOI":"10.1093\/ofid\/ofaa439.1672"},{"issue":"3","key":"2512_CR21","doi-asserted-by":"publisher","first-page":"e0216721","DOI":"10.1128\/aac.02167-21","volume":"66","author":"MJ Lasko","year":"2022","unstructured":"Lasko MJ, Gethers ML, Tabor-Rennie JL, Nicolau DP, Kuti JL. In vitro Time-Kill studies of Trimethoprim\/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli using Cation-Adjusted Mueller-Hinton broth and ISO-Sensitest broth. Antimicrob Agents Chemother. 2022;66(3):e0216721.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2512_CR22","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1093\/jac\/dkac304","volume":"77","author":"MJ Lasko","year":"2022","unstructured":"Lasko MJ, Tabor-Rennie JL, Nicolau DP, Kuti JL. Trimethoprim\/sulfamethoxazole pharmacodynamics against Stenotrophomonas maltophilia in the in vitro Chemostat model. J Antimicrob Chemother. 2022;77(11):3187\u201393.","journal-title":"J Antimicrob Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02512-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02512-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02512-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:19:10Z","timestamp":1757146750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02512-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2512"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02512-0","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the University of Pittsburgh Institutional Review Board (STUDY22070065) with a waiver of written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate and Consent to Publish"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}